The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paperMassimo Cristofanilli, Klaus Pantel, Salvatore Grisanti et al.|Critical Reviews in Oncology/Hematology|2018Cited by 268
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system<b>?</b>Cristina Raimondi, Paola Gazzaniga|OncoImmunology|2017Cited by 78
Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center TrialChiara Nicolazzo, Cristina Raimondi, Gian Maria Busetto et al.|The Oncologist|2019Cited by 54
Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal CancerCristina Raimondi, Paola Gazzaniga|Cancers|2019Cited by 49
The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC)Chiara Nicolazzo, Cristina Raimondi, Gian Maria Busetto et al.|Journal of Cancer Research and Clinical Oncology|2017Cited by 44